ASCO18: Updated Phase 1 results of crizotinib against MET-amplified lung cancer

IMAGE: At ASCO 2018, D. Ross Camidge, MD, PhD, and colleagues report updated phase I results of crizotinib in MET-amplified non-small cell lung cancer. view more 

Credit: University of Colorado Cancer Center

The drug crizotinib has activity against a number of genetic targets relevant to non-small cell lung cancer, already earning FDA-approval against ALK- and ROS1-positive lung cancers. Now updated phase 1 clinical trial results presented at the American Association for Clinical Oncology (ASCO) Annual Meeting 2018 show a 40 percent response rate and 6.7-month median progression-free survival from crizotinib in highly MET-amplified non-small cell lung cancer, as well. The study also identifies new criteria to define “highly MET-amplified” cancer, adjusting the number of MET copies down from 5 per chromosome to 4 per chromosome. By lowering the bar for “high MET amplification”, the study suggests that crizotinib may benefit more MET-amplified patients than previously thought.

The study comes in the context of continuing work to target MET amplification in cancer. While alterations in the gene MET have been known to cause lung and other cancers, and drugs have been developed to target MET, these drugs have been largely unsuccessful in the clinic.

“It may not be that there


Article originally posted at

Click here for the full story

CategoryAggregator News

Privacy Policy / Terms Of Use

Powered by MMD